Planned dosing cohorts
Cohort . | Carfilzomib,* mg/m2 . | Pomalidomide, mg . | Dexamethasone,† mg . |
---|---|---|---|
−3 | 20 | 2 | 40 |
−2 | 27 | 2 | 40 |
−1 | 27 | 3 | 40 |
1 (initial dose level) | 27 | 4 | 40 |
2 | 36 | 4 | 40 |
3 | 45 | 4 | 40 |
4 | 56 | 4 | 40 |
Cohort . | Carfilzomib,* mg/m2 . | Pomalidomide, mg . | Dexamethasone,† mg . |
---|---|---|---|
−3 | 20 | 2 | 40 |
−2 | 27 | 2 | 40 |
−1 | 27 | 3 | 40 |
1 (initial dose level) | 27 | 4 | 40 |
2 | 36 | 4 | 40 |
3 | 45 | 4 | 40 |
4 | 56 | 4 | 40 |
Carfilzomib was administered IV over 30 minutes; pomalidomide was administered orally; dexamethasone was administered either IV or orally.
The first 2 doses of carfilzomib in cycle 1 were to be administered at 20 mg/m2.
Dosing of dexamethasone may be modified at the discretion of the treating investigator.